Definitive Local Therapy for Oligo-recurrence in Patients With Completely Resected Non–small Cell Lung Cancer. (March 2020)
- Record Type:
- Journal Article
- Title:
- Definitive Local Therapy for Oligo-recurrence in Patients With Completely Resected Non–small Cell Lung Cancer. (March 2020)
- Main Title:
- Definitive Local Therapy for Oligo-recurrence in Patients With Completely Resected Non–small Cell Lung Cancer
- Authors:
- Matsuguma, Haruhisa
Nakahara, Rie
Wakamatsu, Ikuma
Kishikawa, Takayuki
Sugiyama, Tomohide
Nakamura, Yoichi
Kasai, Takashi
Kamiyama, Yukari
Hoshi, Nobuo
Inoue, Koichi
Katano, Susumu
Yokoi, Kohei - Abstract:
- Abstract : Background: The aim of this study was to elucidate a curable subgroup among patients with non–small cell lung cancer (NSCLC) who developed postoperative recurrence. Patients and Methods: Between 1986 and 2012, among the 1408 patients who underwent complete anatomic lung resection for NSCLC at our institution, 420 developed recurrence. After excluding 14 patients with insufficient information about recurrence, 406 were included in this retrospective study. We investigated the association between several clinicopathologic factors and postrecurrence overall survival (PR-OS) and postrecurrence progression-free survival (PR-PFS). Results: The 5-year PR-OS and PR-PFS rates were 14.0% and 5.9%, respectively. By multivariate analysis, female sex, longer disease-free interval, specific targeted therapy, recent recurrence, oligo-recurrence, and definitive local therapy (DLT) were found to be independent favorable prognostic factors for both PR-OS and PR-PFS. Among these 6 prognostic factors, although female sex, longer disease-free interval, and specific targeted therapy were associated with a prolonged median PR-PFS time, they were not associated with an improved 5-year PR-PFS rate. In contrast, recent recurrence, oligo-recurrence, and DLT were associated with improvement in both the median PR-PFS time and 5-year PR-PFS rate. Conclusions: We found that recent recurrence, oligo-recurrence, and DLT were associated with an improved median PR-PFS time and long-term PR-PFS rateAbstract : Background: The aim of this study was to elucidate a curable subgroup among patients with non–small cell lung cancer (NSCLC) who developed postoperative recurrence. Patients and Methods: Between 1986 and 2012, among the 1408 patients who underwent complete anatomic lung resection for NSCLC at our institution, 420 developed recurrence. After excluding 14 patients with insufficient information about recurrence, 406 were included in this retrospective study. We investigated the association between several clinicopathologic factors and postrecurrence overall survival (PR-OS) and postrecurrence progression-free survival (PR-PFS). Results: The 5-year PR-OS and PR-PFS rates were 14.0% and 5.9%, respectively. By multivariate analysis, female sex, longer disease-free interval, specific targeted therapy, recent recurrence, oligo-recurrence, and definitive local therapy (DLT) were found to be independent favorable prognostic factors for both PR-OS and PR-PFS. Among these 6 prognostic factors, although female sex, longer disease-free interval, and specific targeted therapy were associated with a prolonged median PR-PFS time, they were not associated with an improved 5-year PR-PFS rate. In contrast, recent recurrence, oligo-recurrence, and DLT were associated with improvement in both the median PR-PFS time and 5-year PR-PFS rate. Conclusions: We found that recent recurrence, oligo-recurrence, and DLT were associated with an improved median PR-PFS time and long-term PR-PFS rate in patients with postoperative recurrence after complete resection of NSCLC. On the basis of these results, we believe that DLT should be considered first for patients with oligo-recurrence before applying noncurative treatment. … (more)
- Is Part Of:
- American journal of clinical oncology. Volume 43:Number 3(2020)
- Journal:
- American journal of clinical oncology
- Issue:
- Volume 43:Number 3(2020)
- Issue Display:
- Volume 43, Issue 3 (2020)
- Year:
- 2020
- Volume:
- 43
- Issue:
- 3
- Issue Sort Value:
- 2020-0043-0003-0000
- Page Start:
- Page End:
- Publication Date:
- 2020-03
- Subjects:
- non–small cell lung cancer -- postrecurrence survival -- oligo-recurrence
Cancer -- Treatment -- Periodicals
Oncology -- Periodicals
Tumors -- Periodicals
616.994005 - Journal URLs:
- http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=toc&D=yrovft&AN=00000421-000000000-00000 ↗
http://www.amjclinicaloncology.com ↗
http://journals.lww.com ↗ - DOI:
- 10.1097/COC.0000000000000656 ↗
- Languages:
- English
- ISSNs:
- 0277-3732
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 0823.500000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 18729.xml